title: Assessment of the pharmacokinetic interaction between zileuton and digoxin in humans.
abstract: The effects of coadministration of zileuton on the pharmacokinetic profile of digoxin were investigated in a double-blind placebo-controlled crossover study in 12 healthy male volunteers. During each study phase, the subjects received zileuton 600mg every 6 hours (regimen A) or placebo (regimen B) for 13 days. In addition, all subjects received concomitant digoxin 0.25 mg/day on study days 1 to 11 during both study phases. The study results provide no evidence of any significant overall effect of zileuton on digoxin plasma concentration-time profiles. Although the mean time to reach the maximum plasma concentration for digoxin was significantly shorter after concomitant administration of digoxin and zileuton than after concomitant administration of digoxin and placebo (0.95 vs 1.43 hours), there were no significant differences between the 2 regimens in the values for maximum plasma concentration, area under the plasma concentration-time curve from 0 to 24 hours, elimination half-life, oral clearance, and apparent volume of distribution associated with the terminal phase. Therefore, it is concluded that digoxin and zileuton may be coadministered without risk of clinically relevant effects on the pharmacokinetic profile of digoxin.
authors.affiliation: Pharmacokinetics and Biopharmaceutics Department, Abbott Laboratories, Abbott Park, Illinois, USA.
authors.forename: W M
authors.initials: WM
authors.lastname: Awni
authors.forename: Z
authors.initials: Z
authors.lastname: Hussein
authors.forename: J H
authors.initials: JH
authors.lastname: Cavanaugh
authors.forename: G R
authors.initials: GR
authors.lastname: Granneman
authors.forename: L M
authors.initials: LM
authors.lastname: Dubé
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000704:Analysis of Variance; D001772:Blood Cell Count / Q000187:drug effects; D002316:Cardiotonic Agents / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D018592:Cross-Over Studies; D004077:Digoxin / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000494:pharmacology; D004311:Double-Blind Method; D004347:Drug Interactions; D004562:Electrocardiography / Q000187:drug effects; D006207:Half-Life; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood / Q000494:pharmacology; D007553:Isotope Labeling; D016859:Lipoxygenase Inhibitors / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D008297:Male; D011863:Radioimmunoassay
chemical_list: D002316:Cardiotonic Agents; D016859:Lipoxygenase Inhibitors; D004077:Digoxin; C063449:zileuton; D006918:Hydroxyurea